Advance Search
ZHOU Xinglu, LU Jiancan, MENG Ying, ZHU Hongling. Effects of dapagliflozin on glucolipid metabolism and levels of renal injury markers in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 74-78. DOI: 10.7619/jcmp.20201394
Citation: ZHOU Xinglu, LU Jiancan, MENG Ying, ZHU Hongling. Effects of dapagliflozin on glucolipid metabolism and levels of renal injury markers in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 74-78. DOI: 10.7619/jcmp.20201394
shu

Effects of dapagliflozin on glucolipid metabolism and levels of renal injury markers in patients with type 2 diabetes mellitus

  • Department of Endocrinology, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135

More Information
  • Received Date: November 08, 2020
  • Available Online: March 22, 2021
  • Published Date: March 14, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To analyze the influence of dapagliflozin on glucolipid metabolism status and levels of renal injury markers such as urine β2 microglobulin (β2-MG) and N-acetyl-β-D-glucosaminidase (NAG) in patients with type 2 diabetes mellitus (T2DM).
      Methods  The data of 54 patients with T2DM who were treated with dapagliflozin (observation group) and not treated with dapagliflozin (control group) in our hospital was retrospectively analyzed. The glucolipid metabolism, blood pressure, body weight, renal function and renal injury indicators before and after treatment and adverse reactions during treatment were recorded in the two groups.
      Results  After 24 weeks of treatment, the levels of peripheral blood fasting blood glucose (FBG), glycated hemoglobin (HbALc), body weight and body mass index (BMI) in the two groups were decreased compared with those before treatment, and the above indexes of observation group were significantly lower than those of control group (P < 0.05). The lipid metabolism indexes in the two groups were improved compared with those before treatment, but there was no statistically significant differences between two groups (P>0.05). After 24 weeks of treatment, the systolic blood pressure (SBP) and levels of urine α1-microglobulin (α1-MG), urine β2-MG and urine NAG in the observation group were significantly decreased compared with those before treatment, and were significantly lower than those in the control group (P < 0.05). There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups during treatment (P>0.05).
      Conclusion  Dapagliflozin has better effects in lowering blood glucose and blood pressure in patients with T2DM, and fewer adverse reactions. It can reduce the partial renal injury markers and may have a renal protective effect.
    • FullText(HTML)
    • References (23)
  • [1]
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67. doi: 10.3760/cma.j.issn.1674-5809.2018.01.003
    [2]
    袁丽, 杨小玲. 糖尿病分层分级管理中自我管理处方应用思考[J]. 中华糖尿病杂志, 2018, 10(5): 314-317. doi: 10.3760/cma.j.issn.1674-5809.2018.05.003
    [3]
    ZOU Z, LI C, PATTON G C. Early-life exposure to the Chinese Famine and subsequent T2DM[J]. Nat Rev Endocrinol, 2020, 16(2): 124-125. doi: 10.1038/s41574-019-0299-y
    [4]
    李静, 李楠, 杨永歆. 2型糖尿病患者胰岛素治疗加用达格列净的疗效及安全性[J]. 国际内分泌代谢杂志, 2018, 38(5): 289-292. doi: 10.3760/cma.j.issn.1673-4157.2018.05.001
    [5]
    SATIRAPOJ B. Sodium-glucose cotransporter 2 inhibitors with renoprotective effects[J]. Kidney Dis: Basel, 2017, 3(1): 24-32. doi: 10.1159/000471765
    [6]
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018(4): 292-344. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201804009.htm
    [7]
    SATO T, AIZAWA Y, YUASA S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J]. Cardiovasc Diabetol, 2018, 17(1): 6-6. doi: 10.1186/s12933-017-0658-8
    [8]
    KARG M V, BOSCH A, KANNENKERIL D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial[J]. Cardiovasc Diabetol, 2018, 17(1): 5-5. doi: 10.1186/s12933-017-0654-z
    [9]
    FADINI G P, ZATTI G, BALDI I, et al. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study[J]. Diabetes Obes Metab, 2018, 20(7): 1781-1786. doi: 10.1111/dom.13280
    [10]
    荆亚莉, 朱大龙. 达格列净和阿卡波糖临床疗效间接比较的系统性综述和Meta分析[J]. 中华糖尿病杂志, 2018, 10(10): 645-653. doi: 10.3760/cma.j.issn.1674-5809.2018.10.004
    [11]
    LEE D M, BATTSON M L, JARRELL D K, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice[J]. Cardiovasc Diabetol, 2018, 17(1): 62-62. doi: 10.1186/s12933-018-0708-x
    [12]
    DÍAZ-RODRÍGUEZ E, AGRA R M, FERNÁNDEZ? ÁL, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability[J]. Cardiovasc Res, 2018, 114(2): 336-346. doi: 10.1093/cvr/cvx186
    [13]
    FIORETTO P, DEL PRATO S, BUSE J B, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study[J]. Diabetes Obes Metab, 2018, 20(11): 2532-2540. doi: 10.1111/dom.13413
    [14]
    SINGH N, BANSAL P, MAITHANI M, et al. Development and validation of a stability-indicating RP-HPLC method for simultaneous determination of dapagliflozin and saxagliptin in fixed-dose combination[J]. New Journal of Chemistry, 2018, 42(3): 902-909. http://pubs.rsc.org/en/content/articlelanding/2018/nj/c7nj04260d/unauth
    [15]
    YU J, CAO Y, YU H Z, et al. A Concise and Efficient Synthesis of Dapagliflozin[J]. Organic Process Research & Development, 2019, 23(7): 1458-1461.
    [16]
    AKKUŞO, AKKUŞG, KAYPAKLI O. The possible effects of dapagliflozin on 12-derived electrocardiogram in patients with type 2 diabetes mellitus[J]. Endocr Metab Immune Disord Drug Targets, 2019, 19(2): 207-213. doi: 10.2174/1871530319666181218121508
    [17]
    CHERNEY D Z I, ZINMAN B, INZUCCHI S E, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5(8): 610-621. doi: 10.1016/S2213-8587(17)30182-1
    [18]
    曹广海, 刘翠华, 张小方. 健脾补肾法联合强的松对脾虚湿困型小儿肾病综合征骨代谢、尿β2-MG及α1-MG的影响[J]. 中国实验方剂学杂志, 2018, 24(5): 176-181. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201805030.htm
    [19]
    崔西春, 马立飞, 周晓光, 等. 儿童肾积水肾功能早期损伤指标的临床应用价值[J]. 中华泌尿外科杂志, 2019, 40(11): 811-815. doi: 10.3760/cma.j.issn.1000-6702.2019.11.003
    [20]
    沈丽莎, 彭文芳, 夏莉莉, 等. 2型糖尿病肾病患者血清Kim-1、尿NAG、AGT水平的表达及临床意义[J]. 实用预防医学, 2018, 25(10): 1252-1255. doi: 10.3969/j.issn.1006-3110.2018.10.030
    [21]
    CAI J, JIAO X, LUO W, et al. Kidney injury molecule-1 expression predicts structural damage and outcome in histological acute tubular injury[J]. Ren Fail, 2019, 41(1): 80-87. doi: 10.1080/0886022X.2019.1578234
    [22]
    OH T J, SUL W J, OH H N, et al. Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment[J]. Sci Rep, 2019, 9(1): 20300. doi: 10.1038/s41598-019-56684-5
    [23]
    牟伦盼, 蒋建家, 张雅萍, 等. 达格列净与利格列汀对口服降糖药控制不佳的超重或肥胖2型糖尿病患者的疗效和安全性比较[J]. 中华糖尿病杂志, 2019, 11(3): 190-195. http://d.wanfangdata.com.cn/periodical/zhtnb201903006
    • Related Articles

  • Related Articles

    [1]LIU Dan, YANG Mingzhu, ZHANG Jiaorui. Levels of serum solute carrier family 7 member 11 and platelet-derived growth factor BB in children with bronchial asthma and their correlations with disease severity[J]. Journal of Clinical Medicine in Practice, 2025, 29(6): 39-44. DOI: 10.7619/jcmp.20244177
    [2]SHAO Zhongxin, LI Shiying. Effect of propofol regulating macrophage polarization on airway inflammatory response and Toll-like receptor 4-NOD-like receptor protein 3 pathway in mice with bronchial asthma[J]. Journal of Clinical Medicine in Practice, 2025, 29(6): 13-19. DOI: 10.7619/jcmp.20245587
    [3]ZHANG Pan, WEI Yuanyuan, WANG Hao, WANG Xianwei, LI Yanqing, SUN Xue. Effect of Callicarpa nudiflora on wound healing and PI3K/AKT/mTOR pathway by regulating M2 macrophage polarization in rats with diabetic foot ulcer[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 44-49, 54. DOI: 10.7619/jcmp.20243269
    [4]MA Jiao, HUO Jingyu, HAN Caiyun. Correlations of serum dual-specific phosphatase 1 and soluble cluster of differentiation 93 with severity of disease, lung function and airway inflammation in children with acute-phase bronchial asthma[J]. Journal of Clinical Medicine in Practice, 2025, 29(3): 118-122. DOI: 10.7619/jcmp.20242394
    [5]WU Lili, LIN Jingtao, ZHANG Yuancheng, ZHONG Peimin, TANG Jinsong, WANG Haibo. Mechanisms of mesenchymal stem cell-derived extracellular vesicles in improvement of renal injury in rats with diabetic nephropathy by regulating mammalian target of rapamycin/p70 ribosome protein S6 kinase/coiled-coil myosin-like Bcl-2-interacting protein pathway[J]. Journal of Clinical Medicine in Practice, 2024, 28(10): 51-57. DOI: 10.7619/jcmp.20232784
    [6]WANG Haitong, LIU Jianliang. Mechanism of naringin on retinal microvascular endothelial cells injury based on adenosine-monophosphate-activated protein kinase/mammalian target of rapamycin pathway[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 23-28. DOI: 10.7619/jcmp.20233233
    [7]HU Xiaolin, HAO Xin, LI Wenqian, ZHAO Tiantian, HOU Sicong. SLC1A5 combined with TM4SF1 regulates the migration of esophageal squamous cell through mTOR signaling pathway[J]. Journal of Clinical Medicine in Practice, 2023, 27(14): 45. DOI: 10.7619/jcmp.20230772
    [8]YI Jinling, Tubikezi·YIBILI, Gulihumaer·AINIWAER, LA Xiaolin. Effect of TAM family receptor tyrosine kinases on signaling pathway of mammalian target of rapamycin in patients with endometriosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 7-12, 16. DOI: 10.7619/jcmp.20223087
    [9]GAO Li, LI Xiaoming, YANG Bo, QIN Ying, CHENG Dong, ZHENG Lifei, LI Li. Long non-coding RNA CBR3-AS1 mediates the mechanism of cytarabine resistance in leukemia cells through the PI3K/AKT/mTOR/S6K pathway[J]. Journal of Clinical Medicine in Practice, 2022, 26(8): 66-70, 75. DOI: 10.7619/jcmp.20214581
    [10]LI Yilong, LEI Kai, ZHANG Xiaozhao, DING Jingjian, ZHANG Shengtao, QIAO Wei, GUO Yongfeng. Study in effects of 1, 25-dihydroxyvitamin D3 on apoptosis and autophagy of colon cancer cells and its mechanism[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 5-9. DOI: 10.7619/jcmp.20211388

  • Cited by

    Periodical cited type(1)

    1. 吴杨. 罗氟司特联合布地奈德对支气管哮喘患者肺功能小气道参数的影响. 中国药物与临床. 2025(03): 192-196 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (537) PDF downloads (32) Cited by(3)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return